<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04741074</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1050</org_study_id>
    <secondary_id>Universal Trial Number</secondary_id>
    <nct_id>NCT04741074</nct_id>
  </id_info>
  <brief_title>Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy</brief_title>
  <acronym>RAISE-KT</acronym>
  <official_title>A RAndomized trIal Examining the Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy for Patients With Stage 4-5 CKD or Dialysis-dependent ESKD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geisinger Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geisinger Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized study evaluates the effect of subcutaneous semaglutide /in combination with&#xD;
      lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity,&#xD;
      and stage 4-5 chronic kidney disease (CKD) or dialysis-dependent end-stage kidney disease&#xD;
      (ESKD) on patients' eligibility for kidney transplantation at the end of 9 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transplant policies regarding listing consider uncontrolled diabetes and severe obesity to be&#xD;
      contraindications though there is great variability for exact BMI (35-45 kg/m2) and A1c&#xD;
      (9-10%) thresholds for listing by center. Glucagon-lowering peptide-1 receptor agonists&#xD;
      (GLP-1 RAs) offer great promise in this population as they have been shown to reduce weight,&#xD;
      central adiposity, A1c, and risk of cardiovascular outcomes with similar effects in patients&#xD;
      with and without CKD.&#xD;
&#xD;
      In this double-blind, placebo-controlled randomized controlled trial, the investigators will&#xD;
      evaluate the effect of subcutaneous semaglutide 1.34 mg/ml (up to 1.0 mg per week) in&#xD;
      combination with lifestyle counseling in patients with T2DM, overweight/obesity, and stage&#xD;
      4-5 CKD or dialysis-dependent ESKD on patients' eligibility for kidney transplantation in&#xD;
      terms of diabetes control (A1c &lt;9%) and obesity (BMI &lt;35 kg/m2 or 35-40 kg/m2 with waist&#xD;
      circumference &lt;120 cm) at the end of 9 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This is a placebo-controlled double-blind clinical trial. Study investigators and participants will be blinded to treatment allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Kidney transplant eligibility</measure>
    <time_frame>Ascertained at the end of 9 months</time_frame>
    <description>Proportion either listed for kidney transplant at 9 months or meeting the following kidney transplant candidacy criteria for A1c (&lt;9%) and obesity (BMI &lt;35 kg/m2 or BMI 35-40 kg/m2 with waist circumference &lt;120 cm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin A1c (HgbA1c)</measure>
    <time_frame>From baseline to 9 months</time_frame>
    <description>HgbA1c will be collected using routine procedures and measured on the same day at the central Geisinger laboratory by Turbidimetric inhibition immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI</measure>
    <time_frame>From baseline to 9 months</time_frame>
    <description>Weight will be measured at each study visit in light clothing without shoes by trained, certified staff using a calibrated, digital scale. Scales will be calibrated annually. Height will be measured at the initial study visit to the nearest 0.1 cm using a calibrated, wall-mounted stadiometer without shoes on a firm, level surface, with head in the horizontal plane.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>From baseline to 9 months</time_frame>
    <description>Waist circumference will be measured at each study visit to the nearest 0.1 cm using a Gulick II tape measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist-to-hip ratio</measure>
    <time_frame>From baseline to 9 months</time_frame>
    <description>Hip circumference will also be measured to the nearest 0.1 cm using a Gulick II tape measure, and waist-to-hip ratio will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body fat percentage</measure>
    <time_frame>From baseline to 9 months</time_frame>
    <description>Measured using bioelectrical impedance analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation on the transplant list</measure>
    <time_frame>Assessed at end of 9 months</time_frame>
    <description>Assessed by Geisinger kidney transplant committee (blinded to randomization assignment, independent of investigators)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receipt of kidney transplant</measure>
    <time_frame>Assessed at end of 9 months</time_frame>
    <description>Confirmed by review of electronic health record (EHR)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Low-Density Lipoprotein (LDL)</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Collected at a Geisinger lab using routine procedures and measured on the same day at the central Geisinger laboratory by spectrophotometry.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in triglycerides</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Collected at a Geisinger lab using routine procedures and measured on the same day at the central Geisinger laboratory by spectrophotometry.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in systolic blood pressure</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Automated office blood pressure (AOBP) will be measured (attended) using the OMRON 907-XL machine, with a 5-minute rest period in the seated position, followed by 3 measurements separated by 1-minute time intervals by trained research staff. Mid-arm circumference will be measured, and a cuff of appropriate size will be identified and the same size cuff will used for both visits.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in diastolic blood pressure</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Automated office blood pressure (AOBP) will be measured (attended) using the OMRON 907-XL machine, with a 5-minute rest period in the seated position, followed by 3 measurements separated by 1-minute time intervals by trained research staff. Mid-arm circumference will be measured, and a cuff of appropriate size will be identified and the same size cuff will used for both visits.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in albuminuria among subset of participants without end-stage kidney disease</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Testing at the central Geisinger laboratory, using immunoturbidimetry (albumin) and Jaffe/Enzymatic (Urine Creatinine)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in estimated glomerular filtration (eGFR) rate among subset of participants without end-stage kidney disease</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Testing at central Geisinger lab; Creatinine-based CKD-EPI equation</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause hospitalizations</measure>
    <time_frame>Entire 9-month study period</time_frame>
    <description>Collected using Geisinger EHR data</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiovascular disease (CVD) events</measure>
    <time_frame>Entire 9-month study period</time_frame>
    <description>Collected using Geisinger EHR data using ICD codes for CVD-related hospitalizations</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion experiencing doubling of creatinine or end-stage kidney disease</measure>
    <time_frame>Entire 9-month study period</time_frame>
    <description>Collected using Geisinger EHR data using ICD codes</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion experiencing death</measure>
    <time_frame>Entire 9-month study period</time_frame>
    <description>Collected using Geisinger EHR data</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion experiencing gastrointestinal disorders</measure>
    <time_frame>Entire 9-month study period</time_frame>
    <description>Assessed at each study visit</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion experiencing gallbladder disorders</measure>
    <time_frame>Entire 9-month study period</time_frame>
    <description>Assessed at each study visit</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion experiencing neoplasms</measure>
    <time_frame>Entire 9-month study period</time_frame>
    <description>Assessed at each study visit</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion experiencing hepatic events</measure>
    <time_frame>Entire 9-month study period</time_frame>
    <description>Assessed at each study visit</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion experiencing allergic reactions</measure>
    <time_frame>Entire 9-month study period</time_frame>
    <description>Assessed at each study visit</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion experiencing injection-site reactions</measure>
    <time_frame>Entire 9-month study period</time_frame>
    <description>Assessed at each study visit</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion experiencing hypoglycemia events</measure>
    <time_frame>Entire 9-month study period</time_frame>
    <description>Assessed at each study visit</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion experiencing acute pancreatitis events</measure>
    <time_frame>Entire 9-month study period</time_frame>
    <description>Assessed at each study visit</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>CKD</condition>
  <condition>Diabetic Kidney Disease</condition>
  <condition>Type 2 Diabetes Mellitus in Obese</condition>
  <condition>Obesity</condition>
  <condition>Severe Obesity</condition>
  <arm_group>
    <arm_group_label>Semaglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive semaglutide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution</intervention_name>
    <description>Dose will be started at 0.25 mg per week. Dose escalation will occur every 4 weeks to mitigate risk of gastrointestinal side effects to a maximum dose of 1.0 mg per week.</description>
    <arm_group_label>Semaglutide</arm_group_label>
    <other_name>semaglutide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution</intervention_name>
    <description>Matched placebo solution for injection will be provided by Novo Nordisk in a 1.5 ml pre-filled pen-injector for subcutaneous injection with the same instructions on dose escalation.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. - Age ≥ 18 years&#xD;
&#xD;
          2. - BMI 25-45 kg/m2&#xD;
&#xD;
          3. - T2DM&#xD;
&#xD;
          4. - Advanced CKD* (last eGFR &lt;30 ml/min/1.73m2 in EHR or ESKD on dialysis prior to&#xD;
             screening)&#xD;
&#xD;
          5. - Fulfill kidney transplant listing criteria except for one or more of the following&#xD;
             reasons (1: uncontrolled diabetes [A1c ≥9%); 2: severe obesity (BMI ≥ 40 kg/m2 or BMI&#xD;
             35-40 kg/m2 with waist circumference &gt;120 cm). See exclusion criteria for general&#xD;
             contraindications used for transplant listing used by majority of U.S. transplant&#xD;
             centers].&#xD;
&#xD;
          6. - Ability to provide informed consent before any trial-related activities&#xD;
&#xD;
          7. - Access to a telephone&#xD;
&#xD;
               -  The cause of the CKD does not need to be due specifically to diabetes&#xD;
&#xD;
        Exclusion Criteria (General contraindications used for transplant listing used by majority&#xD;
        of U.S. transplant centers)&#xD;
&#xD;
          1. - Active malignancy&#xD;
&#xD;
          2. - History of pancreatitis&#xD;
&#xD;
          3. - Active substance abuse&#xD;
&#xD;
          4. - Severe COPD&#xD;
&#xD;
          5. - Pulmonary fibrosis&#xD;
&#xD;
          6. - Symptomatic angina or recent myocardial infarction within 6 months&#xD;
&#xD;
          7. - Severe peripheral vascular disease&#xD;
&#xD;
          8. - Cirrhosis&#xD;
&#xD;
          9. - New York Health Association (NYHA) Class III-IV congestive heart failure&#xD;
&#xD;
         10. - Severe cognitive impairment&#xD;
&#xD;
         11. - Drug addiction&#xD;
&#xD;
         12. - History of non-adherence to therapy&#xD;
&#xD;
         13. - Active infection&#xD;
&#xD;
         14. - Expected life expectancy &lt; 5 years&#xD;
&#xD;
             Additional exclusion criteria&#xD;
&#xD;
         15. - Type 1 diabetes mellitus&#xD;
&#xD;
         16. - History of diabetic ketoacidosis within the last 12 months&#xD;
&#xD;
         17. - Planning on undergoing bariatric surgery in next 9 months.&#xD;
&#xD;
         18. - Pregnant, breast-feeding, or planned pregnancy prior to the end of participation or&#xD;
             not using adequate contraceptive measures&#xD;
&#xD;
         19. - Self-reported average consumption of &gt; 21 alcoholic beverages per week or binge&#xD;
             drinking&#xD;
&#xD;
         20. - Psychiatric hospitalization in past year&#xD;
&#xD;
         21. - Principal investigator discretion (i.e. concerns about safety, compliance)&#xD;
&#xD;
         22. - Known or suspected allergy to trial medication&#xD;
&#xD;
         23. - Previous participation (i.e. randomized) in this trial&#xD;
&#xD;
         24. - Use of GLP1-RA or pramlintide within 90 days prior to screening&#xD;
&#xD;
         25. - Use of metformin (contraindicated with eGFR &lt; 30 ml/min/1.73m2)&#xD;
&#xD;
         26. - Use of DPP-4 inhibitors within 30 days prior to screening&#xD;
&#xD;
         27. - Personal or family history of medullary thyroid cancer, multiple endocrine neoplasia&#xD;
             types 2A and 2B syndrome&#xD;
&#xD;
         28. - Last hemoglobin A1c ≥ 12% or A1c &lt;6% (to avoid risk of hypoglycemia) prior to&#xD;
             screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex R Chang, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geisinger Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Gummo, MPH</last_name>
    <phone>570-214-5147</phone>
    <email>lagummo@geisinger.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Gummo, MPH</last_name>
      <phone>570-214-1547</phone>
      <email>lagummo@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Alex R Chang, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Wyoming Valley</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lauren Gummo, MPH</last_name>
      <phone>570-214-5147</phone>
      <email>lagummo@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Alex Chang, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Geisinger Clinic</investigator_affiliation>
    <investigator_full_name>Alexander Chang</investigator_full_name>
    <investigator_title>Assistant Professor, Clinical Research</investigator_title>
  </responsible_party>
  <keyword>ckd</keyword>
  <keyword>obesity</keyword>
  <keyword>kidney transplant</keyword>
  <keyword>transplant wait list</keyword>
  <keyword>diabetic kidney disease</keyword>
  <keyword>glp-1</keyword>
  <keyword>semaglutide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will become available at the time of publication of the main trial results and will be publicly available indefinitely.</ipd_time_frame>
    <ipd_access_criteria>The deidentified IPD will be publicly available without restrictions.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

